Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.


Confirmed Presenting Companies:

 Session Chair Profile

Ph.D., Founder and CEO, Insilico Medicine, Inc

Biography
Alex Zhavoronkov, PhD, is the founder&CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. He is also the founder of Deep Longevity, developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and insurance industry. Since 2015 he has invented critical technologies in the field of GANs and reinforcement learning for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for the prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. He has published over 130 peer-reviewed research papers and 2 books. He serves on the editorial boards of Trends in Molecular Medicine, Aging Research Reviews, Aging, Frontiers in Genetics, and co-chairs the Annual Aging Research,Drug Discovery, and AI Forum.


 Speaker Profile

Partner, McKinsey and Company

Biography
Ziv Yaar has worked on the topic of Digital & Advanced Analytics for 23 years, across a variety of different industries and in pharma for over 15 years. Ziv has worked across many different industries on the topic of scaling advanced analytics, the key topics that business leaders and managers need to know, how to work with technology and data science organizations, organizational processes design of analytics, best-practices in digital & analytics transformations, and strategy. He has served Merck HH in a variety of different studies over the past 10 years both at the country and global level.


AI and Data Sciences Showcase:
McKinsey and Company

McKinsey and Company is a global management consulting firm.

Data Transformation
McKinsey found that Pharmas need to deliver ~1,000 AI use-cases per year to achieve scale. Most take 4-6 months per use-case. We will review our findings on what leading pharmacos are doing to get that down to 4-6 weeks.

 Speaker Profile

Vice President of Business Development, MMRF

Biography
Christopher Williams was named Vice President of Business Development at the MMRF in 2017, responsible for business development, partnership and joint venture efforts for the foundation. He is a business development leader with a strong scientific background, specializing in the pharmaceutical and diagnostics space. Most recently he served as the VP of Business Development at WaveSense where he was in charge of their US commercialization strategy and product expansion, as well as being responsible for overseeing their strategic partner relationships. Previously Chris was VP of Business Development at SkylineDx, providing commercialization strategy for their oncology portfolio. With PerkinElmer, as the Market Segment Leader in Oncology, he had responsibility for their cancer diagnostic products including strategy, launch activities, external presentations and marketing execution. While at Millennium Pharmaceuticals, Chris held roles in the Protein Science, Technology Development and Proteomics groups. He also had scientific roles at Schering-Plough and the Sandoz Research Institute. Chris holds graduate and post-graduate degrees in Microbiology/Molecular Biology and Protein Biochemistry from Clemson University.


AI and Data Sciences Showcase:
MMRF

A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for every multiple myeloma patient by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer.

Innovation Of Patient-Centered Research Initiatives: MMRF CureCloud
The first-of-its-kind, innovative MMRF CureCloud research study features direct-to-patient enrollment, the first at-home CLIA-grade cfDNA sequencing test for myeloma, and real-world EHR data collection to deliver real-time insights back to patients and their physicians to inform clinical decision-making.

 Speaker Profile

Ph.D., Founder & CEO, QUIBIM

Biography
Angel Alberich-Bayarri is a bioengineer, researcher and entrepreneur in medical image processing and the application of AI methods to radiology. He has experience in the lab-to-market translation of AI models covering unmet clinical needs in neurology, respiratory diseases, musculoskeletal and oncology scenarios. He is author of more than 60 publications in the field of imaging biomarkers, author of more than 15 book chapters and editor of 2 books. He is board member of several scientific societies and panels, such as the European Society of Medical Imaging Informatics (EUSOMII) and the European Imaging Biomarkers Alliance (EIBALL). In March 2020, he was one of the main promoters of the Imaging COVID-19 AI initiative, which currently hosts the biggest worldwide database of COVID-19 CT examinations and is leading the development of a highly accurate model for disease severity scoring and in-patients follow-up. He was named one of MIT Technology Review’s 35 most innovative people in the world under age 35, in 2015.


AI & Data Science Showcase:
QUIBIM

QUIBIM provides an AI platform focused on converting medical images into meaningful data. The company has a portfolio of accurate quantitative imaging solutions across neurology, lung, musculoskeletal and oncology disease areas.

AI and Medical Imaging for Innovation in COVID-19
The presentation will review the main challenges in the field of AI in medical imaging in the most relevant disease scenarios as well as the need for accelerating the lab-to-market transition of tools that can support COVID-19 patients management during the pandemic situation.

 Speaker Profile

MBA, CEO, BeanStock Ventures

Biography
Shawnnah Monterrey is the CEO and founder of BeanStock Ventures, with 20+ years’ experience in medical and life science software product development. BeanStock Ventures is an FDA accredited third party 510(k) review organization. Prior to founding BeanStock Ventures, she obtained a bachelor’s degree in computer science from the University of California, San Diego and an Executive MBA from San Diego State University, then went on to hold product development management positions across numerous global firms, including Illumina, Invetech, Medtronic and Carl Zeiss Meditec. During her time at Carl Zeiss Meditec, Shawnnah and her team successfully launched and obtained several 510(k) clearances for an AI based glaucoma diagnostics and monitoring application, using a neural network and support vector machine, in the early 2000s.


AI & Data Science Showcase:
BeanStock Ventures

BeanStock Ventures is an FDA accredited 3rd party review and software product development organization in the life science, digital health and medical device industry.

FDA Regulation, A Peek into AI Proposed Regulatory Framework
Artificial intelligence applications rely on diverse datasets to make informed decisions. As datasets grow, algorithms improve in sensitivity and specificity. The challenge remains, how to handle this from a regulatory perspective without hindering innovation and delaying products into the market?

 Speaker Profile

Ph.D., Chief Data Scientist & Co-Founder, OneThree Biotech

Biography
Cory Gilvary’s research has primarily focused on developing new machine learning techniques for increasing the efficiency and innovation of drug development and discovery. She takes the unique approach of combining distinct types of noisy, high-throughput data to maximize algorithmic performance, while also building interpretable models that allow for a deeper mechanistic insight to the mode of action of therapeutics. She has leveraged cutting edge AI concepts across diverse disease areas including, but not limited to, oncology, diabetes and Parksinson’s disease. Outside of her biological research, she spent time developing cutting edge machine learning models at one of the world’s leading quantitative hedge funds. Currently, Cory leads OneThree’s data science and computational biology efforts and much of her early research work formed the core OneThree platform. At the beginning of 2020, she spearheaded OneThree’s internal efforts to provide free toxicity screening to any researchers working on treatment for COVID-19.


AI & Data Science Showcase:
OneThree Biotech

OneThree Biotech is a VC backed startup working to change how new medicines are discovered using biology-driven AI. We are clinically validated and work with biotech and pharmaceutical companies to apply our mechanism focused AI to both pre-clinical and clinical pain points.

Interpretable AI for Early Stage Oncology Target Discovery
OneThree has created a platform of mechanism focused algorithms to address key questions within drug discovery. Our interpretable AI, allows us to elucidate the underlying mechanism of our predicted novel targets, a target's expected toxicity, and the ideal patient populations for positioning.

 Speaker Profile

Ph.D., CEO & Founder, PrecisionLife

Biography
Steve has over 25 years’ experience building world-class teams, products and companies including as Global Director of Research Informatics for Astra. He has raised venture funding in the UK, EU and USA to develop and market highly innovative and commercially successful products in the life science, healthcare and food industries. He has developed world-leading genomics, digital health, smart IoT and informatics technologies including several patented inventions. He was heavily involved in developing some of the core informatics systems used by major genomics companies during the initial Human Genome project and has worked extensively with major pharma companies on over 25 drug discovery and safety projects. Steve specializes in AI enabled drug discovery and precision medicine, large-scale genomics, semantic data integration and complex data analytics for life science and healthcare. He is interested in all aspects of precision medicine for chronic disease including novel drug targets, biomarkers and genetic risk scores.


AI & Data Science Showcase:
PrecisionLife

PrecisionLife’s unique combinatorial analytics platform generates deep insights into the complex biology of chronic diseases, driving the next wave of precision medicine applications and finding new treatment opportunities for patients’ unmet medical needs.

Chronic Disease Precision Medicine Needs Combinatorial Analytics
PrecisionLife’s unique combinatorial analytics platform generates deeper insights into the complex biology of chronic diseases, driving the next wave of precision medicine. All significant variant combinations are mapped to patient sub-groups, capturing the non-linear effects of the underlying biology.

 Speaker Profile

Ph.D., CEO, Deepcell

Biography
Maddison is co-founder and CEO of Deepcell. She invented Deepcell’s AI-based single-cell analysis and sorting technology with her postdoctoral advisor Euan Ashley and Mahyar Salek, and spun the company out of Stanford University in 2017. She has a multidisciplinary background with experience in electrical engineering, computer science, and bioengineering. Maddison holds a bachelor’s degree in electrical engineering from Sharif University of Technology, as well as a master’s degree in computer science and a PhD in bioengineering from the University of California, Los Angeles. She has published several papers in top-tier journals and has co-invented multiple patented technologies.


AI & Data Science Showcase:
Deepcell

Deepcell offers an AI-powered imaging and microfluidics platform that identifies and isolates viable cells based on morphological distinctions for use in translational research, diagnostic testing, and therapeutics.

Deep Learning Enables Label-free, Real-time Cell Characterization and Isolation
We present a novel technology for real-time identification and sorting of unlabeled single cells in flow using high-resolution imaging and a Convolutional Neural Network (CNN) across multiple cell types including immune cells, malignant cells, among others.

 Speaker Profile

CEO, Omics Data Automation

Biography
Before starting Omics Data Automation, Gans was the chief architect of several generations of multi-core Xeon processors (2001 – 2013) starting with the first multicore server which resulted in more than 92% server market share for Intel. Starting 2014, he focused on Genomics and Precision Medicine driven by “Big Data”. As Director of the Precision Medicine group at Intel, he led the “Collaborative Cancer Cloud” a federated cloud platform for cancer research, collaborating with OHSU (Oregon Health Science University, OR), Broad Institute, [email protected] and various Cancer medical centers including Dana Farber Cancer Institute in Boston and OICR (Ontario Institute for Cancer Research) in Toronto. He also led Heterogeneous computing group and three Intel collaborations with academic centers at UC Berkeley, Technion Israel and UCLA in this area.


AI and Data Science Showcase:
Omics Data Automation

ODA makes tools that aggregate data from EHR, omics and imaging to provide analytics that improve patient outcomes, reduce cost and expand access.

 Speaker Profile

M.D., Ph.D., SVP, Chief Medical Officer, SOPHiA GENETICS

Biography
Dr. Philippe Menu, MD, PhD, MBA, brings a unique blend of medical expertise across clinical medicine, fundamental research in molecular biology and business management consulting. He joined SOPHiA GENETICS in 2020 from McKinsey & Company, where he had spent the last 8 years serving dozens of clients in the BioPharma sector, advising global pharmaceutical companies, mid-size players and biotechs alike across the pharma value chain with a major focus on innovative therapies and diagnostics in oncology and rare diseases. Philippe obtained his MD and PhD from the University of Lausanne, and his MBA in life sciences from the Open University Business School.


AI & Data Science Showcase:
SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 750 hospital, laboratory and biopharma institutions globally.

Leveraging Multimodal Insights for Drug Development
Discover how we partner with the biopharma community to identify biomarkers and pioneer multimodal predictive analytics.

 Speaker Profile

Ph.D., Head of Translational Sciences, VeriSIM Life

Biography
Dr. Chakravarty leads external research collaborations and pursues opportunities and defines scientific applications of the BIOiSIM platform. He works specifically in the areas of preclinical data translatability, relevant endpoints, and exhaustive review of preclinical models, leveraging our AI/ML platform for the acceleration of the drug development process for potential shortening of the timeline to IND and NDA. His research and development experience encompasses metabolic disease, physiology, in vivo pharmacology, and translational science. He has been in the drug discovery space for 15+ years with one of his antisense compounds completing Phase II clinical trials recently. Prior to VeriSIM Life, Chakravarty led teams at Pfizer, Roche, and NASA. He holds a Ph.D. in Nutrition and Biochemistry from Case Western Reserve University. He has published 18+ peer-reviewed scientific articles, delivered talks at several conferences, and received numerous awards for his contributions.


AI & Data Science Showcase:
VeriSIM Life

VeriSIM Life created a platform that enables AI-driven bio-simulations to de-risk drug R&D decisions by predicting the value before human trials.

AI-driven Accelerated Therapeutics Development for COVID-19
We use in silico modeling using BIOiSIM, an AI-integrated mechanistic modeling platform by utilizing known preclinical in vitro and in vivo datasets to accurately simulate systemic therapy disposition and site-of-action penetration of the investigational compounds implicated in COVID 19 pathogenesis.

 Speaker Profile

Co-Founder and Chief Technology Officer, Syntegra

Biography
Ofer Mendelevitch has led technical development at Syntegra since its inception, where he has pioneered the use of generative language models to create synthetic healthcare data. Prior to joining Syntegra, Ofer served as Vice President of Data Science at Helix, a population genomics company. He has extensive experience leading complex state-of-the-art machine learning software projects across industries, having previously led data science and engineering teams at several companies, including LendUp, Hortonworks and Yahoo!. Ofer has published several papers and is the author of the book, “Practical Data Science with Hadoop and Spark.”


AI & Data Science Showcase:
Syntegra

Syntegra is the first healthcare company to leverage the breakthrough of machine learning language models (similar to GPT-3) to create patient-level, synthetic healthcare data that maintains full statistical fidelity and patient privacy, enabling increased data use and value across healthcare.

Innovative Machine Learning Models to Democratize Healthcare Data
AI-enabled synthetic data offers a unique solution to the long-standing challenges inhibiting access to healthcare data. We will discuss how modern language models are used by the Syntegra engine to generate synthetic healthcare data with high fidelity and guaranteed privacy.

 Speaker Profile

Chief Science Officer, BC Platforms

Biography
Timo Kanninen is CTO and co-founder of BC Platforms. He is the visionary behind BC Platforms’ data management systems. He has long-term experience in software development, genetic epidemiology, statistical genetics, and clinical statistics. Mr. Kanninen has also worked with hospital and occupational health IT systems. Mr. Kanninen is the founder and CEO/CTO of Statwell Oy (1990‐2002). The company provided statistical consultation and developed software for data collection and statistical analyses of personnel and occupational health questionnaires. The company was merged into BC Platforms in 2002. Mr. Kanninen studied information technology in production and statistics. He is a co-author on 16 scientific articles published in high-level journals.


AI & Data Science Showcase:
BC Platforms

BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine and drug development, accelerating the translation of insights into clinical practice.

 Speaker Profile

Ph.D., CEO, VIDA

Biography
Dr. Wood has 25 years’ experience championing innovative clinical solutions into routine clinical use. She was recognized as one of the top 50 CEOs by Healthcare Technology Report; she also received the Joe Rosenfeld Award for outstanding leadership. In addition to serving as CEO of VIDA, she is currently a board member for iCAD, serves on the Board of Governors at the University of Maryland, and is past Chair of the Board of Visitors of the Graduate School at Duke University. Dr. Wood received her Ph.D. from Johns Hopkins Medical Institutions, School of Hygiene and Public Health. Her Ph.D. work combined quantifying three-dimensional lung structure with changes in lung function using high-resolution CT imaging. She also holds a Master of Science degree in Biomedical Engineering from Duke University, and a Bachelor of Science in Engineering from the University of Maryland, College Park.


AI & Data Science Showcase:
VIDA

VIDA delivers precision lung intelligence to accelerate the therapy pipeline. Our AI-powered analysis is quantitative and actionable, making a breakthrough in the staggering time and cost of respiratory trials.

The Disruptive Impact of Precision Lung Data on Respiratory Trial
Lung clinical trials are expensive & time consuming. Learn how data is harnessed to accelerate respiratory trials by delivering superior endpoints, identifying subjects and streamlining operations. Through AI and precision lung metrics, we're making breakthroughs in the staggering time and cost of trials.

 Speaker Profile

Ph.D., Senior Scientist, Predictive Oncology

Biography
Molecular, Cell and Computational Biologist. Founder and executive manager of both private and public traded life sciences companies, presently focused on translation of latest machine learning and genomics technology platforms towards development of next generations personalized oncology and precision drug development. Author of two textbooks in Human Genomics, dozens of peer-reviewed publications, and developer of dozens of statistical genetics, LIMS and machine learning life sciences software applications including most recently, a suite of machine learning programs for application of single cell next generation sequencing for precision drug development and per-patient chemosensitivity testing. Original prior work identified the major genetic determinants of the dominant anthropometric traits as well as global patterns of deep biogeographical ancestry admixture, and in early 2000s trailblazed today’s forensic phenotyping and genetic genealogy marketplaces with the introduction of the world’s first consumer genomics products.


AI & Data Science Showcase:
Predictive Oncology

At Predictive Oncology, we believe that we are at the threshold of a new frontier in cancer research and drug therapies. And the key to the looming discoveries is Artificial Intelligence.

ML for Personalized Chemosensitivity and Precision Pharma
Since the early 2000’s Predictive Oncology’s ChemoFX assay has been doubling ovarian cancer patient survival through personalized chemosensitivity testing. We are applying new cell culture advances, genomics platform technologies and machine learning tools to elevate this assay for precision drug development.

 Speaker Profile

M.D., Chief Medical Science Officer, Sema4; Clinical Professor of Medicine, Tisch Cancer Inst., Mount Sinai

Biography
William K. Oh, M.D. is Chief Medical Science Officer at Sema4, a patient-centered health intelligence company focused on precision medicine. He is also an internationally recognized medical oncologist with over 25 years of clinical and translational research experience and leadership roles at major NCI-designated cancer centers. He continues to see cancer patients in his capacity as Clinical Professor of Medicine at Icahn School of Medicine at Mount Sinai. William has authored more than 330 articles, reviews, books and book chapters related to genitourinary cancers. He has conducted multiple clinical cancer trials and has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association.


 Speaker Profile

M.B.A., Co-Founder, CEO; Endpoint Health

Biography
Jason is an accomplished start-up founder and executive with experience developing and commercializing disruptive products to solve healthcare’s most challenging problems. He is currently co-founder, board member and CEO of Endpoint Health, a Precision First therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each individual patient’s biology. Prior to Endpoint Health, co-founded GeneWEAVE, a diagnostics company that developed novel solutions to improve diagnosis and therapy choice in drug-resistant infections. Started in 2010, GeneWEAVE raised $25M in venture financing and was acquired by Roche in 2015. Jason received an MBA from Cornell University and currently lives in San Jose, CA with his wife and daughters.


AI & Data Science Showcase:
Endpoint Health

Endpoint Health is a precision first therapeutics company dedicated to addressing urgent needs in immune-driven illnesses by delivering therapies that are personalized to each patient’s biology by combining therapeutics and AI into an integrated platform.

Rewriting the Rules in Precision-First BioPharma
Learn how Endpoint Health is building a clinical and data ecosystem to dramatically accelerate development of life-changing immunology therapies personalized to each patient’s biology. Combining therapeutics and AI, the Company is unlocking value for patients, doctors, and healthcare systems.

 Speaker Profile

CEO, IMIDomics

Biography
Juan Harrison is a biotechnology and pharmaceutical executive focused on company formation, strategy, partnering, venture investment and licensing transactions. In his current role at IMIDomics, he is leading the company as it works to discover and develop new medicines for the treatment of patients with immune-mediated inflammatory diseases. He was previously Vice President and head of Strategic Academic Alliances (SAA) at Takeda Pharmaceuticals where he was responsible for establishing several broad drug discovery alliances. Before leading Takeda’s SAA, he was vice president at Takeda Ventures where he invested in several companies including Envoy Therapeutics, later acquired by Takeda. Harrison has also held senior positions in Alza Pharmaceuticals, Connetics, PowderJect and XenoPort.


AI & Data Science Showcase:
IMIDomics

With strong roots in Spain and an established presence in the United States, IMIDomics is a global biotechnology company focused on the discovery and development of new medicines for the treatment of patients with immune-mediated inflammatory diseases (IMIDs).

IMIDomics’ Precision Discovery Platform Enables Precision Medicine
IMIDomics believes that a deep understanding of patients, their clinical condition and underlying biology will lead to next generation medicines. Juan Harrison will showcase how IMIDomics discovers and develops precision medicines for IMIDs using its proprietary data-powered system.

 Speaker Profile

Ph.D., CEO and Co-Founder, Healx

Biography
Tim is a tech entrepreneur from the Cambridge Cluster, passionate about using AI to accelerate treatments for rare diseases. He is Co-Founder and Chief Executive of Healx, the mission-driven technology company pioneering the next wave of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. In this role, Tim has been listed in The Sunday Times Maserati 100 list in 2019, was featured in The Telegraph’s Tech 100 in 2019, and was named as ‘One to watch’ in The Telegraph’s Top 50 Most Ambitious Business Leaders in 2020. Tim is also the Co-Founder and Trustee of the Cambridge Rare Disease Network (CRDN). Prior to Healx and CRDN, he obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience, developing nanobody technology for Parkinson's disease.


AI and Data Sciences Showcase:
Healx

Healx combines frontier AI technology with deep drug discovery and development expertise to accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development.

Pioneering the Next Generation of Drug Discovery for Rare Disease
There are 7,000 rare diseases, affecting over 400 million people worldwide - and 95% of those diseases don’t have an approved treatment. Hear how Healx are developing a new approach to drug discovery in order to address this huge unmet need.

 Speaker Profile

Ph.D., Data Scientist, Ardigen

Biography
Dr. Krzysztof Rataj works at the intersection of medicinal chemistry, biology, imaging and artificial intelligence in the field of drug discovery. He obtained a PhD in Biophysics from Jagiellonian University, and worked on numerous projects in collaboration with scientific teams from Hungary, Denmark and Norway. His team explores the application of artificial intelligence approaches to various aspects of drug design and precision medicine, such as transformers for property prediction and compound optimization, natural language processing methods in protein and nucleic acid research, and computer vision in high content screening and histopathology. Their current endeavor is the marriage of chemical structure and phenotypic screening images in order to create a comprehensive approach to high content screening.


AI & Data Science Showcase:
Ardigen

Ardigen is harnessing advanced AI methods for novel precision medicine. The company’s in-house datasets, together with advanced AI platforms, empower the development of effective therapies.

Enhancing Phenotypic Drug Discovery with AI-based Methods
The resurgence of phenotypic screening as a viable method of early drug discovery opens up a new field for application of AI-based methods. We would like to explore the concept of merging high content image data with chemical compound data to provide new quality in HCS pipelines.

 Speaker Profile

Ph.D., Director of Scientific Strategy and Business Development, Aiforia

Biography
Dr. Thomas Westerling-Bui received his PhD in cancer biology, focusing on the cell cycle and transcription, from the University of Helsinki Medical School in Finland. He completed a post-doctoral EMBO fellowship at the Dana Farber Cancer Institute in Boston, researching the genomics of breast and prostate cancer. Thomas joined Aiforia to advance the new potential of cancer biology, pathology, big data, and artificial intelligence.


AI and Data Sciences Showcase:
Aiforia

Aiforia equips pathologists and scientists with powerful deep learning artificial intelligence for translating images into discoveries, decisions, and diagnoses. The cloud based Aiforia software aims to escalate the efficiency and precision of preclinical and clinical medical image analysis from oncology to neuroscience and more.

Bringing Precision to Diagnostics with Deep Learning
Deep learning artificial intelligence enables increased speed, accuracy and consistency in medical image analysis. Aiforia's automated, AI-driven solutions supports pathologists in diagnosing some of the most prevalent cancers like breast and lung with greater efficiency and precision; paving the path for personalized therapy.

 Speaker Profile

Sr. Manager & Head, Academic Medicine, Amazon Web Services (AWS)

Biography
Ken leads the AWS Academic Medicine Vertical which includes a team of Principal Trusted Advisors in Digital Health, Hospital Modernization, Precision Medicine, Clinical Care and Informatics, and HealthTech sub-verticals, and a team of field based and customer facing Healthcare Executive Advisors. He has over 30 years of healthcare experience, including founding and taking public a cell and gene therapy company. Prior experience includes being a Chief Clinical Officer, President and CEO for 10 years prior to joining AWS. Ken has a strong background in building and commercializing regulated products in the device, combination product, clinical software, and therapeutic biologics space.


AI and Data Science Showcase:
Amazon

AWS for Health is used by thousands of healthcare customers globally. It provides proven and easily accessible capabilities that help organizations increase the pace of innovation, unlock the potential of health data, and develop more personalized approaches to therapeutic development and care.

Digital Health Data Strategy – The First Step in Precision Medicine
Linking big data at the patient level is essential to enable physicians and researchers to truly test their precision medicine hypothesis. However, different types of data have various value, and it is important for institutions to prepare and implement an upfront data plan that powers research. In this talk, we will present various technology approaches to link and validate existing PHI data.

 Speaker Profile

Senior Vice President & General Manager, Data Products & AI, Tempus

Biography
Abdul Hamid Halabi serves as the Senior Vice President & General Manager, Data Products and AI. Prior to Tempus, Abdul was the Global Head of Healthcare, AI and Robotics at NVIDIA. Abdul launched NVIDIA’s Health platform, Clara, to reach thousands of developers and deployment sites. He also grew NVIDIA’s healthcare industry presence to a healthy 9-figure and accelerating business. Abdul holds a B.S. in Computer Engineering from the University of Toronto, a Master’s in Management Science and Engineering from Stanford University and an MBA from Texas A&M-Commerce.


AI and Data Science Showcase:
Tempus

Tempus is bringing the power of artificial intelligence to healthcare by building the world’s largest library of molecular and clinical data and a platform to make that data accessible and useful. We provide genomic sequencing services and analyze molecular and therapeutic data at scale to empower physicians and researchers to make real-time, data-driven decisions.

 Speaker Profile

Ph.D., CEO, Quinten Healthcare

Biography
Billy graduated from Ecole Polytechnique, AgroParisTech and holds a multiple-awards-winning PhD in Decision Mathematics from Paris-Dauphine University. Over the past 20 years, Billy has developed quantitative methodologies to inform and support strategic decision making in healthcare. He created and led data-driven decision support teams in major public and private organisations. He served as statistical or modeling expert for public Health Authorities (e.g. EFSA, ANSES, WHO, Gates Foundation) and supported 100+ regulatory or reimbursement dossier submissions worldwide. Billy authored 100+ publications, and led hundreds of data modeling or machine learning projects. He is now CEO of Quinten Health, the Real-World Disease Modeling company.


AI and Data Science Showcase:
Quinten Health

As a European leader in artificial intelligence and machine learning, Quinten Health masters interpretable real-world data science, together with predictive disease modeling and cohort simulations. Quinten Health accelerates, de-risks and optimizes data-driven and value-based decision making for health agencies, care providers and pharma industry.

AI-powered Disease Modeling in Real-world for Optimal Decisions
The purpose of this talk is to propose a regulatory-grade, data-integrative and disease-centric approach to accelerate and de-risk trials while maximizing the real-world value of the products in development. We use reference disease modeling plaftorms enabling for virtual cohort simulations.

 Speaker Profile

Senior Manager, Partnerships, PathAI

Biography
Robert Brockett has spent most of his career as a scientist in histopathology, developing immunohistochemistry assays and image analysis strategies. He has a M.S. degree in Clinical and Translational Research, a B.S. in Biology, and is a certified Histotechnologist.


AI and Data Science Showcase:
PathAI

PathAI is a leading provider of AI-powered research tools and services for pathology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.

AI-Powered Pathology for Prospective Clinical Trials
Learn about PathAI's clinical trial and drug development AI tools for patient selection, endpoint analysis, or manual reads quality control

 Speaker Profile

Ph.D., Co-Founder and CEO, MIMs

Biography
Sarah Jenna is the co-founder and CEO of My Intelligent Machines (MIMs) and was previously an associate professor specialized in genomics and genetics at UQÀM. Sarah received her Ph.D. in Cell and Structural Biology, from Aix-Marseille University in France. She completed her postdoctoral training in cell signalling at McGill University and was Platform Manager of the Montréal Proteomic Network. In 2006, her dual expertise in cellular and genomic signalling led her to be awarded a NSERC (Natural Sciences and Engineering Research Council of Canada) Junior Canada Research Chair in Integrative Genomics and Cell Signaling at UQÀM. At the helm of MIMs, she translates her 20 years of experience and expertise to provide clients with cutting-edge integrative genomics strategies & systems biology while paying particular attention to the specific needs of life scientists working in BioPharma, and research institutes. She was part of the Top 10 Most Influential Women Leaders in 2021 by Exeleon Magazine.


AI and Data Science Showcase:
MIMs

Founded in 2016, Montreal-based My Intelligent Machines (MIMs) is a leader in artificial intelligence & systems biology. MIMs provides Biopharma companies with easy-to-implement augmented intelligence systems, allowing for accurate biological simulations at early R&D stages, to assist life scientists in the development of targeted and personalized therapies.

Use of Augmented Intelligence for Target and Biomarker Discovery
At MIMs, we have developed a unique augmented intelligence system that enables life scientists to capitalize on machine-based computer modelling, distributed computing & federated learning while leveraging their own expertise in life sciences, to identify targets with more clinical potential than classical bioinformatic approaches.